Mechanism of Action and Clinical Efficacy of CDK4/6 Inhibitors in BRCA-Mutated, Estrogen Receptor-Positive Breast Cancers: Case Report and Literature Review

Sensitivity to endocrine therapy of patients with estrogen receptor (ER)-positive metastatic breast cancer and germline BRCA1/2 mutations is not yet fully elucidated. Furthermore, the registration trials of CDK 4/6 inhibitors in combination with endocrine therapy lacked of a pre-specified subgroup a...

Descripción completa

Detalles Bibliográficos
Autores principales: Militello, Anna Maria, Zielli, Teresa, Boggiani, Daniela, Michiara, Maria, Naldi, Nadia, Bortesi, Beatrice, Zanelli, Paola, Uliana, Vera, Giuliotti, Sara, Musolino, Antonino
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2019
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6700293/
https://www.ncbi.nlm.nih.gov/pubmed/31456944
http://dx.doi.org/10.3389/fonc.2019.00759

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6700293/
https://www.ncbi.nlm.nih.gov/pubmed/31456944
http://dx.doi.org/10.3389/fonc.2019.00759

Ejemplares similares